Drugs for Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 114)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Dacarbazine |
Approved, Investigational |
Phase 2, Phase 3 |
|
4342-03-4 |
2942 5351166 |
Synonyms:
(E)-DACARBAZINE
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
Biocarbazine
Biocarbazine R
Carboxamide, dimethyl imidazole
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
Decarbazine
Deticene
DIC
Dimethyl imidazole carboxamide
|
Dimethyl triazeno imidazole carboxamide
Di-me-triazenoimidazolecarboxamide
DTCI
DTIC
DTIC dome
Dtic-dome
DTICDome
DTIC-DOME (TN)
DTIE
HSDB 3219
ICDMT
ICDT
Imidazole carboxamide
Imidazole carboxamide, dimethyl
IMIDAZOLE-4-CARBOXAMIDE, 5-(3,3-DIMETHYL-1-TRIAZENO)-
NCI C04717
NCI-C04717
NSC 45388
NSC-45388
|
|
2 |
|
Doxorubicin |
Approved, Investigational |
Phase 2, Phase 3 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
3 |
|
Ifosfamide |
Approved |
Phase 2, Phase 3 |
|
3778-73-2 |
3690 |
Synonyms:
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Asta Z 4942
Holoxan
Ifex
Ifosfamid
Ifosfamida
IFOSFAMIDE
Ifosfamide sterile
Ifosfamidum
Ifosphamide
Ifsofamide
Iphosphamid
|
Iphosphamide
I-phosphamide
Iso endoxan
Iso-endoxan
Isofosfamide
Isophosphamide
Isosfamide
MITOXANA
MJF-9325
NSC-109724
Z-4942
|
|
4 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2, Phase 3 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
5 |
|
Daunorubicin |
Approved |
Phase 2, Phase 3 |
|
20830-81-3 |
30323 |
Synonyms:
(+)-Daunomycin
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Cerubidin
Cerubidine
Daunamycin
Daunarubicinum
Dauno rubidomycine
Daunoblastin
Daunoblastine
Daunomycin
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
DAUNORUBICIN
Daunorubicin Hcl
Daunorubicin hydrochloride
Daunorubicin, Hydrochloride
DAUNORUBICINA
|
DAUNORUBICINE
Daunorubicinum
Daunorubicinum [INN-Latin]
Dauno-rubidomycine
DaunoXome
DM
DM1
FI 6339
FI-6339
Hydrochloride, daunorubicin
Leukaemomycin C
NDC-0082-4155
NSC-83142
Ondena
Rcra Waste No. U059
RP 13057
Rp 13057 Hydrochloride
RP-13057
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
VALRUBICIN IMPURITY, DAUNORUBICIN
|
|
6 |
|
Mechlorethamine |
Approved, Investigational |
Phase 2, Phase 3 |
|
51-75-2 |
4033 |
Synonyms:
2,2'-Dichloro-N-methyldiethylamine
b,Beta'-dichlorodiethyl-N-methylamine
beta,Beta'-dichlorodiethyl-N-methylamine
BIS (2-CHLOROETHYL) METHYLAMINE
Bis(2-chloroethyl)methylamine
Bis(b-chloroethyl)methylamine
Bis(beta-chloroethyl)methylamine
Bis(β-chloroethyl)methylamine
Caryolysine
Chlorethazine
Chlormethine
Chlormethinum
Cloramin
Clormetina
Embichin
HN2
HN-2
Hydrochloride N-oxide, mechlorethamine
Hydrochloride, mechlorethamine
MBA
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethamine hydrochloride N oxide
Mechlorethamine hydrochloride N-oxide
Mechlorethamine N oxide
Mechlorethamine N-oxide
Mechlorethamine oxide
Mechloroethamine
Mecloretamina
|
Merck brand OF mechlorethamine hydrochloride
Merck frosst brand OF mechlorethamine hydrochloride
Methylbis(2-chloroethyl)amine
Methylbis(b-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methylbis(β-chloroethyl)amine
Methylchlorethamine
Mitomen
Mustargen
Mustine
Nitrogen mustard
Nitrogen mustard N oxide
Nitrogen mustard N-oxide
NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE
Nitrogranulogen
Nitromin
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(b-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis(β-chloroethyl)amine
N-Oxide, mechlorethamine hydrochloride
N-Oxide, nitrogen mustard
NSC 762
NSC-10107
NSC-128663
NSC-762
Β,beta'-dichlorodiethyl-N-methylamine
β,β'-dichlorodiethyl-N-methylamine
|
|
7 |
|
Temozolomide |
Approved, Investigational |
Phase 2, Phase 3 |
|
85622-93-1 |
5394 |
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
BRN 5547136
CCRG 81045
CCRG-81045
CCRIS 8996
m & b 39831
m And b 39831
m And b39831
m And b-39831
M&B 39831
M&B-39831
M-39831
MB 39831
Methazolastone
NSC 362856
NSC-362856
|
SCH 52365
SCH-52365
Temodal
Temodar
TEMOMEDAC
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide
Témozolomide
Temozolomide hexyl ester
Temozolomidum
Temozolomidum [Latin]
TMZ
TMZ Bioshuttle
TMZA-he
TMZ-Bioshuttle
|
|
8 |
|
Olaparib |
Approved |
Phase 2, Phase 3 |
|
763113-22-0 |
23725625 |
Synonyms:
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
AZ2281
AZ-2281
AZD2281
AZD-2281
AZD-2281|AZD2281|Lynparza®
|
KEYLYNK-010 COMPONENT OLAPARIB
KU-0059436
KU59436
KU-59436
Lynparza
OLAPARIB
OLAPARIB COMPONENT OF KEYLYNK-010
|
|
9 |
|
Lenograstim |
Approved, Investigational |
Phase 3 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
10 |
|
Bevacizumab |
Approved, Investigational |
Phase 3 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
11 |
|
Palifosfamide |
Investigational |
Phase 2, Phase 3 |
|
31645-39-3 |
100427 |
Synonyms:
Ifosfamide mustard
Ifosforamide mustard
IPAM
Iphosphoramide mustard
IPM
Isophosphamide mustard
Isophosphoramide mustard
N,N'-BIS-(2-CHLOROETHYL)PHOSPHORIC ACID
|
N,N'-di-(2-chloroethyl)phosphorodiamidic acid
NN'-Bis-(2-chloroethyl)phosphate
NN'-Bis-(2-chloroethyl)phosphoric acid
NSC-297900
Palifosfamide
Palifosfamide-tris
ZIO-201
Zio-201isophosphamide mustard
|
|
12 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
13 |
|
Anti-Bacterial Agents |
|
Phase 2, Phase 3 |
|
|
|
14 |
|
Antibiotics, Antitubercular |
|
Phase 2, Phase 3 |
|
|
|
15 |
|
Liposomal doxorubicin |
|
Phase 2, Phase 3 |
|
|
|
16 |
|
Poly(ADP-ribose) Polymerase Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
17 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
18 |
|
Antibodies, Monoclonal |
|
Phase 3 |
|
|
|
19 |
|
Antibodies |
|
Phase 3 |
|
|
|
20 |
|
Antineoplastic Agents, Immunological |
|
Phase 3 |
|
|
|
21 |
|
Angiogenesis Inhibitors |
|
Phase 3 |
|
|
|
22 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
23 |
|
Immunoglobulins, Intravenous |
|
Phase 3 |
|
|
|
24 |
|
Immunoglobulin G |
|
Phase 3 |
|
|
|
25 |
|
Endothelial Growth Factors |
|
Phase 3 |
|
|
|
26 |
|
Mitogens |
|
Phase 3 |
|
|
|
27 |
|
Coenzyme M |
Approved, Investigational |
Phase 2 |
|
3375-50-6 |
598 23662354 |
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-Mercaptoethanesulphonic acid
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
Bristol myers squibb brand OF mesna
|
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzym m
Coenzyme m
CoM
D-7093
HS-CoM
Kendrick brand OF mesna
Mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
NSC-113891
Reduced coenzyme m
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
Β-mercaptoethanesulfonate
Β-mercaptoethanesulfonic acid
Β-mercaptoethanesulphonate
Β-mercaptoethanesulphonic acid
|
|
28 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239 |
Synonyms:
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 43-9006|BAY-439006|Nexavar®
BAY-43-9006
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
|
Nexavar
SORAFENIB
Sorafénib
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
Sorafenibum
|
|
29 |
|
Progesterone |
Approved, Vet_approved |
Phase 2 |
|
57-83-0 |
5994 |
Synonyms:
(1S,2R,10S,11S,14S,15S)-14-ACETYL-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
(8S,9S,10R,13S,14S,17S)-17-ACETYL-10,13-DIMETHYL-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
(8S,9S,10R,13S,14S,17S)-17-ETHANOYL-10,13-DIMETHYL-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
(S)-4-PREGNENE-3,20-DIONE
(S)-PREGN-4-EN-3,20-DIONE
(S)-PROGESTERONE
17ALPHA-PROGESTERONE
17A-PROGESTERONE
17Α-PROGESTERONE
3,20-PREGNENE-4
4-PREGNEN-3,20-DIONE
4-PREGNENE-3,20-DIONE
AGOLUTIN
AKROLUTIN
Amen
BETA-PROGESTERONE
BIO-LUTON
CIDR
COLPROSTERONE
CORLUTIN
CORLUTINA
CORLUVITE
CORPORIN
CORPUS LUTEUM HORMONE
CRINONE
CRINONE PROGESTERONE GEL
CURRETAB
CYCLOGEST
CYCLOGESTERIN
Cycrin
D4-PREGNENE-3,20-DIONE
DELALUTIN
DELTA(4)-PREGNENE-3,20-DIONE
DELTA(SUP 4)-PREGNENE-3,20-DIONE
DURAPROGEN
ENDOMETRIN
ESTIMA
FLAVOLUTAN
FOLOGENON
Gelbkoerperhormon
GELBKÖRPERHORMON
GESTEROL
GESTEROL 100
GESTEROL 50
GESTIRON
GESTONE
GESTORMONE
GESTRON
GLANDUCORPIN
GYNLUTIN
GYNOLUTON
GYNOLUTONE
HORMOFLAVEINE
HORMOLUTON
Hydroxyprogesterone caproate
Hydroxyprogesterone caproic acid
LINGUSORBS
LIPO-LUTIN
LUCORTEUM
LUCORTEUM SOL
LUGESTERON
LUTEAL HORMONE
Luteinique
LUTEOCRIN NORMALE
LUTEODYN
LUTEOGAN
LUTEOHORMONE
LUTEOL
LUTEOPUR
LUTEOSAN
LUTEOSTAB
LUTEOVIS
LUTEUM
LUTEX
LUTIDON
LUTIGEST
|
Lutin
LUTOCICLINA
LUTOCUCLIN M
LUTOCYCLIN
LUTOCYCLIN M
LUTOCYLIN
LUTOCYLOL
LUTOFORM
LUTOGYL
LUTOGYNON
LUTREN
LUTROMONE
MEMBRETTES
METHYLPREGNONE
MPA
NALUTRON
NSC-64377
NSC-9704
PERCUTACRINE
PERCUTACRINE LUTEINIQUE
PIAPONON
PRANONE
PREGN-4-EN-3,20-DIONE
PREGN-4-ENE-3,20-DIONE
PREGNENE-3,20-DIONE
PREGNENEDIONE
PRIMOLUT
PROCHIEVE
PROGEFFIK
PROGEKAN
PROGESTA-CARE
PROGESTAN
PROGESTASERT
PROGESTEROL
PROGESTERON
PROGESTERONA
Progesterona [INN-Spanish]
PROGESTERONE
PROGESTÉRONE
Progesterone, (13 alpha,17 alpha)-(+-)-isomer
Progesterone, (17 alpha)-isomer
Progesterone, (9 beta,10 alpha)-isomer
PROGESTERONUM
Progesteronum [INN-Latin]
PROGESTIN
PROGESTOGEL
PROGESTOL
PROGESTON
PROGESTONE
PROGESTOSOL
PROGESTRON
PROGESTRONOL
PROJESTAJECT
PROLETS
PROLIDON
PROLUTIN
PROLUTON
PROLUTONE
PROMETRIUM
Prometrium®|Utrogestan®
PRONTOGEST
PROTORMONE
REGUMATE
SERENITY FOR WOMEN
SYNGESTERONE
SYNGESTRETS
SYNGESTRONE
SYNOVEX S
SYNTOLUTAN
Thiuram E
Thiuranide
U 3672
UTROGEST
UTROGESTAN
VITARRINE
Δ(4)-pregnene-3,20-dione
|
|
30 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
31 |
|
Thalidomide |
Approved, Investigational, Withdrawn |
Phase 2 |
|
50-35-1 |
5426 |
Synonyms:
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(+-)-THALIDOMIDE
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(±)-THALIDOMIDE
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
3-PHTHALIMIDOGLUTARIMIDE
Algosediv
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
ALPHA-N-PHTHALYLGLUTARAMIDE
alpha-Phthalimidoglutarimide
Asidon 3
Asmadion
Asmaval
Bonbrain
Bonbrrin
Calmore
Calmorex
Celgene brand OF thalidomide
Contergan
Corronarobetin
Distaval
Distaxal
Distoval
Ectiluran
Enterosediv
Gastrinide
Glupan
Glutanon
Grippex
Hippuzon
Imida-Lab
Imidan
Imidene
Isomin
K-17
Kedavon
Kevadon
Lulamin
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Neaufatin
Neo
Neosedyn
Neosydyn
Nerosedyn
Neufatin
Neurodyn
Neurosedin
Neurosedym
Neurosedyn
Nevrodyn
Nibrol
Noctosediv
Noxodyn
|
N-Phthalimidoglutamic acid imide
N-Phthaloylglutamimide
N-Phthalylglutamic acid imide
N-PHTHALYL-GLUTAMINSAEURE-IMID
NSC-527179
NSC-66847
Pangul
Pantosediv
Poly-Giron
Polygripan
Predni-Sediv
Pro-ban M
Profarmil
Psycholiquid
Psychotablets
Quetimid
Quietoplex
Sandormin
Sedalis
Sedalis sedi-lab
Sedimide
Sedin
Sedisperil
Sedoval
Shin-naito S
Shinnibrol
Sleepan
Slipro
Softenil
Softenon
Talargan
TALIDEX
TALIDOMIDA
Talimol
Talismol
Telagan
Telargan
Telargean
Tensival
Thaled
Thalidomide
THALIDOMIDUM
Thalidomine usp26
Thalin
Thalinette
Thalomid
Theophilcholine
Valgis
Valgraine
Yodomin
Α-(N-PHTHALIMIDO)GLUTARIMIDE
Α-N-PHTHALYLGLUTARAMIDE
Α-PHTHALIMIDOGLUTARIMIDE
|
|
32 |
|
Dexamethasone acetate |
Approved, Investigational, Vet_approved |
Phase 2 |
|
1177-87-3 |
3680 |
Synonyms:
16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate
2-{1-fluoro-14,17-dihydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethyl acetic acid
9alpha-Fluoro-16alpha-methylprednisolone acetate
DECADRON-LA
Dexamethasone 21-acetate
|
DEXAMETHASONE ACETATE
Dexamethasone acetate anhydrous
Dexamethasone acetate, anhydrous
Dexamethasone acetic acid
Dexamethasoni acetas
|
|
33 |
|
Dexamethasone |
Approved, Investigational, Vet_approved |
Phase 2 |
|
50-02-2 |
3003 5743 |
Synonyms:
[<sup>3</sup>H]-dexamethasone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16a-Methyl-9a-fluoro-1-dehydrocortisol
16Α-methyl-9α-fluoro-1-dehydrocortisol
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16a-methyl-9a-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
9a-Fluoro-16a-methylprednisolone
9a-Fluoro-16BETA-methylprednisolone
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-Fluoro-16alpha-methyl-prednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9Α-fluoro-16α-methylprednisolone
Adexone
Aeroseb-D
Aeroseb-dex
Ak dex OPH otic soln 0.1%
Alcon brand OF dexamethasone
alpha -Fluoro-16-alpha -methylcortisol
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (veterinary)
Bisu DS
Calonat
Corson
Corsone
Cortisumman
DALALONE
Decacort
Decacortin
Decaderm
Decadron
Decadron Tablets, Elixir
Decadron®|desametasone|fluormethylprednisolone
DECADRON-75
DECADRON-LA
Decagel
Decaject
Decaject l.a.
Decaject-l.a.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
DEX
DEXA
Dexa mamallet
DEXACEN-4
Dexacidin
Dexacort
Dexacortal
Dexa-cortidelt
Dexacortin
Dexa-cortisyl
DEXACORTISYL
Dexadeltone
Dexafarma
DEXAFREE
DEXAIR
Dexalona
Dexaltin
Dexa-Mamallet
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
DEXAMETHASONE
Dexaméthasone
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
DEXAMETHASONE METASULFOBENZOATE SODIUM
DEXAMETHASONE PALMITATE
Dexamethasone sodium phosphate
|
DEXAMETHASONE VALERATE
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexa-scheroson
Dexa-sine
Dexason
Dexasone
Dexasone 0.5MG
Dexasone 0.75MG
Dexasone 4MG
Dexasporin
Dex-ide
Dexinolon
Dexinoral
Dexone
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
Dexonium
Dexpak
DEXSOL
Dextelan
DEXTENZA
DEXYCU KIT
Dezone
Dinormon
DROPODEX
DXM
DXM833
DXMS
ECR brand OF dexamethasone
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy brand OF dexamethasone
Gammacorten
GPPE EAR SPY
Hexadecadrol
Hexadrol
Hexadrol elixir
Hexadrol Tablets
HL-Dex
ICN brand OF dexamethasone
IontoDex
Isopto-dex
ISV-305
KORTICO INJECTION
Lokalison F
Loverine
Luxazone
MARTAPAN
Maxidex
Maxidex ont 0.1%
Maxidex sus 0.1%
Maxitrol
Mediamethasone
Merck brand OF dexamethasone
Merz brand 1 OF dexamethasone
Merz brand 2 OF dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
Mymethasone
Naquasone (veterinary)
NEODECADRON
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
NSC 34521
NSC-34521
Ocu-trol
Oradexon
OTO-104
OTOMIZE
OZURDEX
Pet derm III
Pet-Derm Iii
PHL-Dexamethasone
PMS Dexamethasone elixir 0.5mg/5ML
PMS-Dexamethasone
Policort
Posurdex
Prednisolon F
Prednisolone F
Prodex
Sandoz dexamethasone
SK-Dexamethasone
SOFRADEX
SPERSADEX COMP
Spoloven
Sunia sol D
Superprednol
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
Visumetazone
|
|
34 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
35 |
|
Benzocaine |
Approved, Investigational |
Phase 2 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
36 |
|
Tannic acid |
Approved |
Phase 2 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
37 |
|
Aflibercept |
Approved |
Phase 2 |
|
862111-32-8 |
124490314 |
Synonyms:
AFLIBERCEPT
AFLIBERCEPT (GENETICAL RECOMBINATION)
AVE0005
AVE-0005
BAY86-5321
BAY-865321
|
BAY-86-5321
EYLEA
VEGF TRAP
VEGF TRAP-EYE
ZALTRAP
ZIV-AFLIBERCEPT
|
|
38 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
39 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 2 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
40 |
|
Romidepsin |
Approved, Investigational |
Phase 2 |
|
128517-07-7 |
5352062 |
Synonyms:
ANTIBIOTIC FR 901228
CHROMADAX
DEPSIPEPTIDE
FK228
FK-228
FK228|FR901228|Istodax®
FR901228
|
FR-901228
ISTODAX
NSC-630176
ROMIDEPSIN
Romidepsina
Romidepsine
Romidepsinum
|
|
41 |
|
Zoledronic acid |
Approved |
Phase 2 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
ácido zoledrónico
ACLASTA
Aclasta®|CGP-42446|CGP-42446A|Reclast®|zoledronate|Zometa®
ANHYDROUS ZOLEDRONIC ACID
CGP-42446
CGP-42446A
Novartis brand OF zoledronic acid
|
Reclast
ZERLINDA
ZOL
ZOL446
ZOLEDRONATE
Zoledronic acid
Zoledronic acid anhydrous
ZOLEDRONIC ACID HYDRATE
ZOLEDRONIC ACID MONOHYDRATE
ZOLEDRONIC ACID, ANHYDROUS
Zometa
Zometa Concentrate
|
|
42 |
|
Dinutuximab |
Approved, Investigational |
Phase 2 |
|
1363687-32-4 |
|
Synonyms:
CH14.18
CH14.18-UTC
DINUTUXIMAB
|
DINUTUXIMAB BETA
Monoclonal antibody ch14.18
UNITUXIN
|
|
43 |
|
Fulvestrant |
Approved, Investigational |
Phase 2 |
|
129453-61-8 |
17756771 104741 |
Synonyms:
(1S,9R,11S,14S,15S)-15-Methyl-9-[9-(4,4,5,5,5-pentafluoropentanesulphinyl)nonyl]tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2,4,6-triene-5,14-diol
(7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol
7-(9-(4,4,5,5,5-Pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
Faslodex
Faslodex®|ICI 182,780|ICI 182780|ICI182780|ZD-9238
|
FULVESTRANT
ICI 182,780
ICI-182780
SID29215034
ZD-9238
|
|
44 |
|
Rituximab |
Approved |
Phase 2 |
|
174722-31-7 |
|
Synonyms:
ABP-798
ANTICD20
CT-P10
HS006
HS-006
HS-006 (RITUXIMAB BIOSIMILAR)
HSDB 7455|IDEC-C2B8|MabThera®|Rituxan®
IDEC-102
IDEC-C2B8
IG GAMMA-1 CHAIN C REGION
Ig gamma-2A chain C region, membrane-bound form
MABTHERA
MABTHERA RITUXAN
|
R-105 IDEC-102
radiolabeled murine anti-CD20
RG-105
RHCACD20MA
RITUXAN
RITUXIMAB
rituximab-abbs
rituximab-arrx
rituximab-pvvr
SAIT101
SAIT-101
Zevalin
|
|
45 |
|
Valganciclovir |
Approved, Investigational |
Phase 1, Phase 2 |
|
175865-60-8 |
64147 |
Synonyms:
Cymeval
Ganciclovir L-valyl ester
L-Valine, ester with ganciclovir
RO-1079070/194
RS-079070-194
|
Valcyt
Valcyte
VALGANCICLOVIR
Valganciclovir hydrochloride
|
|
46 |
|
Cemiplimab |
Approved, Investigational |
Phase 1, Phase 2 |
|
1801342-60-8 |
|
Synonyms:
CEMIPLIMAB
CEMIPLIMAB-RWLC
cemiplimab-rwlc|Libtayo®|REGN-2810|REGN2810|SAR-439684|SAR439684
|
LIBTAYO
REGN2810
REGN-2810
|
|
47 |
|
Talimogene laherparepvec |
Approved, Experimental, Investigational |
Phase 2 |
|
1187560-31-1 |
|
Synonyms:
|
48 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
49 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
50 |
|
Rucaparib |
Approved, Investigational |
Phase 2 |
|
283173-50-2 |
9931954 |
Synonyms:
AG014699
AG-014699
AG-014699|AG014699|AG14447|PF-01367338|Rubraca®
AG14447
AG-14447
|
AG-14447ag-014699Rucaparib
PF-01367338
Rubraca
RUCAPARIB
Rucaparibum
|
|
Interventional clinical trials:
(show top 50)
(show all 130)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age |
Completed |
NCT00346164 |
Phase 3 |
doxorubicin hydrochloride;ifosfamide |
2 |
Randomised Phase III Multicentric Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin in Non-progressive Patients Versus Doxorubicine Alone as First-line Therapy in Patients With Metastatic or Unresectable Leiomyosarcoma (Uterine or Soft Tissue) |
Completed |
NCT02997358 |
Phase 3 |
Doxorubicin;Trabectedin |
3 |
Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma |
Completed |
NCT01692678 |
Phase 3 |
Trabectedin;Dacarbazine |
4 |
A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma |
Completed |
NCT01343277 |
Phase 3 |
Trabectedin;Dacarbazine |
5 |
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma |
Recruiting |
NCT05269355 |
Phase 2, Phase 3 |
Unesbulin;Dacarbazine |
6 |
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) |
Recruiting |
NCT04031677 |
Phase 3 |
Preoperative chemotherapy |
7 |
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma |
Active, not recruiting |
NCT03016819 |
Phase 3 |
AL3818;Dacarbazine;AL3818 or placebo |
8 |
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) |
Active, not recruiting |
NCT02180867 |
Phase 2, Phase 3 |
Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride |
9 |
A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients With Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy |
Not yet recruiting |
NCT05432791 |
Phase 2, Phase 3 |
Olaparib;Pazopanib;Temozolomide;Trabectedin |
10 |
A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients With Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy |
Not yet recruiting |
NCT05633381 |
Phase 2, Phase 3 |
Olaparib;Temozolomide;Trabectedin;Pazopanib |
11 |
A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus |
Terminated |
NCT01012297 |
Phase 3 |
Docetaxel;Gemcitabine Hydrochloride |
12 |
A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma |
Terminated |
NCT01533207 |
Phase 3 |
Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride |
13 |
Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma |
Withdrawn |
NCT03773510 |
Phase 3 |
Trabectedin discontinuation;Trabectedin continuation |
14 |
A Phase II Study of Combination Therapy of a Protracted Oral Schedule of Temozolomide and Thalidomide as First-Line or Subsequent Therapy for Patients With Metastatic, Locally Advanced or Unresectable Leiomyosarcoma |
Unknown status |
NCT00033709 |
Phase 2 |
temozolomide;thalidomide |
15 |
GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum |
Unknown status |
NCT02587169 |
Phase 1, Phase 2 |
Nilotinib-adriamycin |
16 |
Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall |
Unknown status |
NCT03651375 |
Phase 2 |
Sequential chemotherapy - 3 courses of AI |
17 |
A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma |
Completed |
NCT00659360 |
Phase 2 |
saracatinib |
18 |
A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse |
Completed |
NCT02131480 |
Phase 2 |
Doxorubicin;Trabectedin |
19 |
A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas |
Completed |
NCT00245102 |
Phase 2 |
sorafenib tosylate |
20 |
A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas |
Completed |
NCT01154452 |
Phase 1, Phase 2 |
Gamma-Secretase Inhibitor RO4929097;Vismodegib |
21 |
A Phase II Randomized - Non Comparative - Study on the Activity of Trabectedin or Gemcitabine + Docetaxel in Metastatic or Locally Relapsed Uterine Leiomyosarcoma Pretreated With Conventional Chemotherapy |
Completed |
NCT02249702 |
Phase 2 |
gemcitabine + docetaxel;trabectedin |
22 |
A Phase II Study of Mocetinostat Administered With Gemcitabine for Patients With Metastatic Leiomyosarcoma With Progression or Relapse Following Prior Treatment With Gemcitabine-Containing Therapy |
Completed |
NCT02303262 |
Phase 2 |
Mocetinostat;Gemcitabine |
23 |
Open-label, Phase II Trial of Eribulin in Combination With Gemcitabine in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma |
Completed |
NCT03810976 |
Phase 2 |
Eribulin, gemcitabine |
24 |
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma |
Completed |
NCT02247544 |
Phase 2 |
Trabectedin |
25 |
Phase 2 Clinical Study of Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma |
Completed |
NCT00856050 |
Phase 2 |
letrozole |
26 |
A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus |
Completed |
NCT00378911 |
Phase 2 |
sunitinib malate |
27 |
A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus |
Completed |
NCT00025220 |
Phase 2 |
Thalidomide |
28 |
Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus |
Completed |
NCT00005643 |
Phase 2 |
pegylated liposomal doxorubicin hydrochloride |
29 |
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus |
Completed |
NCT01637961 |
Phase 2 |
Alisertib |
30 |
A Phase II Evaluation of Docetaxel and Gemcitabine Plus G-CSF in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus |
Completed |
NCT00031629 |
Phase 2 |
Docetaxel;Gemcitabine Hydrochloride |
31 |
A Phase II Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus |
Completed |
NCT00101127 |
Phase 2 |
docetaxel;gemcitabine hydrochloride |
32 |
A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma |
Completed |
NCT00004066 |
Phase 2 |
docetaxel;gemcitabine hydrochloride |
33 |
A Phase 2 Multi Center Open Label Study of ARQ 501 in Adult Patients With Recurrent, Persistent or Metastatic Leiomyosarcoma |
Completed |
NCT00310518 |
Phase 2 |
ARQ 501 |
34 |
Adjuvant Treatment of High Risk Uterine Leiomyosarcoma With Gemcitabine/Docetaxel Followed by Doxorubicin: A Phase II Trial |
Completed |
NCT00282087 |
Phase 2 |
gemcitabine, docetaxel, doxorubicin |
35 |
A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide |
Completed |
NCT00060944 |
Phase 2 |
Yondelis;Dexamethasone |
36 |
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus |
Completed |
NCT01220609 |
Phase 2 |
Ixabepilone |
37 |
Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma |
Completed |
NCT00400569 |
Phase 2 |
Sunitinib Malate (SU011248) |
38 |
A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET |
Completed |
NCT00668148 |
Phase 2 |
|
39 |
Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors |
Completed |
NCT00815945 |
Phase 2 |
PegLiposomal Doxorubicin;Carboplatin |
40 |
A Phase II Study of M6620 (VX-970) in Selected Solid Tumors |
Completed |
NCT03718091 |
Phase 2 |
M6620 |
41 |
Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma |
Completed |
NCT00837148 |
Phase 2 |
Sorafenib and Dacarbazine |
42 |
A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung |
Completed |
NCT00503295 |
Phase 2 |
|
43 |
A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas |
Completed |
NCT00390234 |
Phase 2 |
ziv-aflibercept |
44 |
A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma |
Completed |
NCT00093080 |
Phase 2 |
ridaforolimus |
45 |
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors |
Completed |
NCT01614795 |
Phase 2 |
Temsirolimus |
46 |
Phase II Trial Of Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes |
Completed |
NCT00887809 |
Phase 2 |
gemcitabine;docetaxel;bevacizumab |
47 |
A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas |
Completed |
NCT00356031 |
Phase 2 |
Bevacizumab |
48 |
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma |
Completed |
NCT01653028 |
Phase 2 |
Alisertib |
49 |
A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas |
Completed |
NCT00112463 |
Phase 2 |
romidepsin |
50 |
Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas |
Completed |
NCT01442662 |
Phase 2 |
pazopanib + gemcitabine |
Cochrane evidence based reviews: leiomyosarcoma
|